Molecular architecture responsible for specific inhibition of oncogenic PI3Kα mutants by RLY-2608 and STX-478

Xiao Liu, Yanyan Chen, Guanyi Li, Anqi Chen, Qingtong Zhou, Ming-Wei Wang

Open source

DOI
10.1016/j.apsb.2026.07.003
Published
2026-09
Container
Acta Pharmaceutica Sinica B
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.apsb.2026.07.003,
  title = {Molecular architecture responsible for specific inhibition of oncogenic PI3Kα mutants by RLY-2608 and STX-478},
  author = {Xiao Liu and Yanyan Chen and Guanyi Li and Anqi Chen and Qingtong Zhou and Ming-Wei Wang},
  year = {2026},
  journal = {Acta Pharmaceutica Sinica B},
  doi = {10.1016/j.apsb.2026.07.003},
  url = {https://doi.org/10.1016/j.apsb.2026.07.003}
}

RIS

TY  - JOUR
TI  - Molecular architecture responsible for specific inhibition of oncogenic PI3Kα mutants by RLY-2608 and STX-478
AU  - Xiao Liu
AU  - Yanyan Chen
AU  - Guanyi Li
AU  - Anqi Chen
AU  - Qingtong Zhou
AU  - Ming-Wei Wang
PY  - 2026
JO  - Acta Pharmaceutica Sinica B
DO  - 10.1016/j.apsb.2026.07.003
UR  - https://doi.org/10.1016/j.apsb.2026.07.003
ER  - 

APA

Liu, X., Chen, Y., Li, G., Chen, A., Zhou, Q., & Wang, M. (2026). Molecular architecture responsible for specific inhibition of oncogenic PI3Kα mutants by RLY-2608 and STX-478. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2026.07.003

Source records